ResearcherSt. Luke's HospitalActive in the last 2 years

Elena Fountzilas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4884-2544; OpenAlex author ID A5089796322. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Phase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma (RACI… Co-author DOI 10.1016/j.ctarc.2026.101481 ↗
Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers13020198 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

George Papaxoinis · 2 shared papers, 2021–2026 · strength 0.34
- Paper Phase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with … DOI 10.1016/j.ctarc.2026.101481 ↗
- Paper Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. DOI 10.3390/cancers13020198 ↗
George Fountzilas · 2 shared papers, 2021–2026 · strength 0.34
- Paper Phase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with … DOI 10.1016/j.ctarc.2026.101481 ↗
- Paper Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. DOI 10.3390/cancers13020198 ↗
Ioannis Kotsantis · 1 shared paper, 2026 · strength 0.25
- Paper Phase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with … DOI 10.1016/j.ctarc.2026.101481 ↗
George E. Pentheroudakis · 1 shared paper, 2026 · strength 0.25
- Paper Phase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with … DOI 10.1016/j.ctarc.2026.101481 ↗
Georgios Oikonomopoulos · 1 shared paper, 2021 · strength 0.09
- Paper Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. DOI 10.3390/cancers13020198 ↗
Christos Dervenis · 1 shared paper, 2021 · strength 0.09
- Paper Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. DOI 10.3390/cancers13020198 ↗
George Zarkavelis · 1 shared paper, 2021 · strength 0.09
- Paper Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. DOI 10.3390/cancers13020198 ↗
Dimitrios G. Pectasides · 1 shared paper, 2021 · strength 0.09
- Paper Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. DOI 10.3390/cancers13020198 ↗
Nikolaos K. Kentepozidis · 1 shared paper, 2021 · strength 0.09
- Paper Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. DOI 10.3390/cancers13020198 ↗
Philippos C. Patsalis · 1 shared paper, 2021 · strength 0.09
- Paper Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. DOI 10.3390/cancers13020198 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.